Skip to main content

Drug Interactions between esomeprazole and taletrectinib

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

esomeprazole taletrectinib

Applies to: esomeprazole and taletrectinib

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Coadministration with inhibitors of the proton pump (PPIs), potassium-competitive acid blockers (PCABs), and H2 receptor antagonists (H2RAs) may decrease the gastrointestinal absorption and plasma concentrations of taletrectinib, which may reduce the therapeutic effectiveness of the drug. Taletrectinib displays pH-dependent aqueous solubility, with increased solubility at lower pH. In a clinical study, coadministration of the PPI omeprazole (40 mg daily) decreased taletrectinib peak plasma concentration (Cmax) by 65% and systemic exposure (AUC) by 40%. While specific clinical data with PCABs and H2RAs are not available, the possibility of reduced or subtherapeutic effectiveness of taletrectinib should be considered.

MANAGEMENT: Concomitant use of taletrectinib with PPIs, PCABs, and H2RAs should be avoided. If acid suppression is necessary, consider alternatives such as locally acting antacids administered at least 2 hours before or 2 hours after taletrectinib dosing. Patients should be advised to contact their doctor if their symptoms worsen or their condition changes, as reduced drug absorption may lead to decreased therapeutic effectiveness.

Drug and food/lifestyle interactions

Major

taletrectinib food/lifestyle

Applies to: taletrectinib

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Coadministration with grapefruit juice may increase the plasma concentrations of taletrectinib. The proposed mechanism for the interaction is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit. Inhibition of hepatic CYP450 3A4 may also contribute. The interaction has not been studied with grapefruit juice but has been reported for other CYP450 3A4 inhibitors. In a clinical study, taletrectinib peak plasma concentration (Cmax) increased by 1.8-fold and systemic exposure (AUC) increased by 3.3-fold following concomitant administration of itraconazole, a potent CYP450 3A inhibitor. According to the product labeling, administration of taletrectinib with a moderate CYP450 3A inhibitor is predicted to increase taletrectinib Cmax and AUC by up to 1.5- and 2.6-fold, respectively. Increased exposure to taletrectinib may increase the risk and/or severity of adverse effects such as hepatotoxicity with liver enzyme elevations, lung toxicities, QT prolongation, hyperuricemia, myalgia with creatine phosphokinase elevation, and skeletal fractures.

ADJUST DOSING INTERVAL: Coadministration with high-fat food (1000 calories, 50% fat) increased taletrectinib Cmax and AUC by 1.5-fold, and the predicted increase in the QTc interval is 20.5 msec.

MANAGEMENT: The manufacturer recommends avoiding food or drink containing grapefruit during treatment with taletrectinib. In addition, taletrectinib should be administered on an empty stomach at about the same time each day, at least 2 hours before or 2 hours after food intake.

Moderate

esomeprazole food/lifestyle

Applies to: esomeprazole

Food may interfere with the absorption of esomeprazole. Esomeprazole should be taken at least one hour before meals and at the same time every day. When esomeprazole is given to patients receiving continuous enteral nutrition (tube feedings), the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole. This will make it easier for your body to absorb the medication. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.